株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のファーマコビジランス市場:治験段階別、サービスプロバイダー別、タイプ別、エンドユーザー別、地域別 - 成長、動向、予測

Pharmacovigilance Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 613115
出版日 ページ情報 英文 115 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.20円で換算しております。
Back to Top
世界のファーマコビジランス市場:治験段階別、サービスプロバイダー別、タイプ別、エンドユーザー別、地域別 - 成長、動向、予測 Pharmacovigilance Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年03月01日 ページ情報: 英文 115 Pages
概要

慢性疾患罹患率の上昇による薬剤有害反応件数の増加が医療制度に大きな負担となっています。世界のファーマコビジランス市場は2018~2023年にかけCAGR12.8%となる見通しです。

当レポートでは、世界のファーマコビジランス市場について調査し、市場の概要と成長動向、競合動向、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響因子

第5章 市場概要

  • 現在の市場シナリオ
  • ポーターズファイブフォース分析

第6章 促進因子、阻害因子、機会、課題分析

  • 促進因子
  • 阻害因子
  • 市場機会
  • 課題

第6章 市場セグメンテーション

  • 治験段階別
    • 前臨床
    • 第1相
    • 第2相
    • 第3相
    • 第4相
  • サービスプロバイダー別
    • 社内
    • 業務委託
  • タイプ別
    • 自発報告
    • ADR特化報告
    • 標的自発報告
    • コホートイベントモニタリング
    • HERマイニング
  • エンドユーザー別
    • 病院
    • 研究機関
    • 産業界
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第8章 競合環境

  • 合併・買収
  • 協定、連携、提携
  • 新製品上市

第9章 主要企業

  • Accenture
  • Clinquest Group B.V.
  • Cognizant
  • Laboratory Corporation of America Holdings
  • IBM Corporation
  • ArisGlobal
  • ICON Plc
  • Capgemini
  • ITClinical
  • iMEDGlobal
  • Foresight Group International AG
  • TAKE Solutions Ltd.
  • PAREXEL International Corporation
  • BioClinica
  • Wipro Ltd.
  • United BioSource Corporation

第10章 市場の将来

目次
Product Code: 57011

Market Overview

The key factors propelling this market are increasing drug consumption and drug development rates, growing incidence rates of adverse drug reactions and drug toxicity, and increasing trend of outsourcing pharmacovigilance services. The increasing incidence of lifestyle diseases, such as diabetes, hypertension, and cardiac disorders, as a result of sedentary lifestyles, lack of physical activities, changing lifestyle patterns, and poor diets lead to increasing consumption of drugs, which, in turn, indicates the high demand for drug monitoring and further fuels the growth of the pharmacovigilance market. With the growing drug consumption, the need for the regular monitoring of drugs has also augmented, eventually boosting the pharmacovigilance market. Human infectious diseases are also on rising due to the changing climate, pervasive poverty, and increasing urbanization, which also surge drug consumption and drive the drug development process. Furthermore, new drug developments need to get regulated and stimulate the overall pharmacovigilance market.

Scope of the Report

Pharmacovigilance is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The focus of pharmacovigilance is on ADR (adverse drug reactions) and drug toxicity. The pharmacovigilance market comprises of all types of adverse events reporting conducted during clinical trials in hospitals, pharmacies, and other healthcare sectors.

Key Market Trends

Pharmaceutical Companies are Expected to Hold the Highest Market Share in the End User Segment

In the end user segment of the pharmacovigilance market, pharmaceutical companies are believed to have the largest market size.

The role of pharmaceutical companies is to invest in the R&D of new compounds, have the commitment to bring a new drug to market to enhance the patients' health and quality of life, strict governance to conduct clinical trials, product development activities as well as conduct relations with patients and healthcare professionals in accordance with ethical and legal principles. A major pharmaceutical company, such as Astra, has over 100 permanent, experienced staff in pharmacovigilance within its R&D organization in Sweden and the United Kingdom, and a similar number in local operating companies worldwide. This development has been driven by the increased recognition of the role of pharmacovigilance, the investigation, and marketing of a wider range of diverse medicinal products and more stringent and detailed regulatory requirements.

Such developments that are occurring in the pharmaceutical companies are helping the pharmacovigilance market grow.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America currently dominates the market for pharmacovigilance and is expected to continue its stronghold for a few more years. Due to the shifting of high costs of in-house pharmacovigilance activities to CROs, the pharmacovigilance system in the United States is moving from a passive to a proactive role in the healthcare system. According to a 2017 publication in the Journal of American Medical Association, one out of three drugs in the United States may have the safety issues. Therefore, a need for modifying the current protocols for quick communication between healthcare providers and the FDA needs to be strengthened. Additionally, as more biosimilars would be available in the near future, accurately matching the adverse event is highly important. With that, the United States has a large market share of 56% in North America and is expected to register a growth rate of 12.3% over the forecast period.

Competitive Landscape

The pharmacovigilance market is moderately competitive and consists of several major players. In terms of market share, a few of the major players currently dominate the market. Companies like Accenture, IBM Corporation, Wipro, Cognizant, and Capgemini hold the substantial market share in the pharmacovigilance market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Drug Consumption And Drug Development Rates
    • 4.2.2 Growing incidence rates of ADR and drug toxicity
    • 4.2.3 Increasing trend of outsourcing pharmacovigilance services
  • 4.3 Market Restraints
    • 4.3.1 High risk associated with data security
    • 4.3.2 Lack of global regulatory harmonization and lack of data standardization for adverse event collection
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Clinical Trial Phase
    • 5.1.1 Preclinical
    • 5.1.2 Phase I
    • 5.1.3 Phase II
    • 5.1.4 Phase III
    • 5.1.5 Phase IV
  • 5.2 Service Provider
    • 5.2.1 In house
    • 5.2.2 Contract Outsourcing
  • 5.3 Type of Reporting
    • 5.3.1 Spontaneous Reporting
    • 5.3.2 Intensified ADR Reporting
    • 5.3.3 Targeted Spontaneous Reporting
    • 5.3.4 Cohort Event Monitoring
    • 5.3.5 EHR Mining
  • 5.4 End User
    • 5.4.1 Hospitals
    • 5.4.2 Pharmaceutical Companies
    • 5.4.3 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 US
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 UK
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East & Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East & Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Accenture
    • 6.1.2 Cognizant
    • 6.1.3 Laboratory Corporation of America Holdings
    • 6.1.4 IBM Corporation
    • 6.1.5 ArisGlobal
    • 6.1.6 Foresight Group International AG
    • 6.1.7 ICON PLC
    • 6.1.8 Capgemini
    • 6.1.9 United BioSource Corporation
    • 6.1.10 Wipro Ltd
    • 6.1.11 BioClinica

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top